WEXFORD, Pa., and MIAMI, Fla., April 19, 2022 /PRNewswire/ — Coeptis Therapeutics, Inc. (OTC PINK: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing innovative cell therapy platforms for cancer, and Bull Horn Holdings Corp. (Nasdaq: BHSE) (“Bull Horn”), a special purpose acquisition company (SPAC), today announced they have entered into a definitive merger agreement for a business combination that will result in Coeptis becoming a wholly-owned subsidiary of Bull Horn. Under the terms of the merger agreement, a wholly-owned subsidiary of Bull Horn will merge with and into Coeptis and the holders of the outstanding Coeptis shares will receive equity in Bull Horn valued at $175 million (subject to adjustments).
Bridgeway Capital Partners and Meister Seelig & Fein PLLC served as financial and legal advisors, respectively, to Coeptis. Jones Trading and Ellenoff Grossman & Schole PLLC served as financial and legal advisors, respectively, to Bull Horn.
Denis A. Dufresne
Partner | Corporate